Patents
Methods for identifying factors for differentiating definitive endoderm
Patent Number: 7,541,185Continuing its tradition of IP excellence, Novocell took a very interesting angle in the current patent. Covered are tests for identifying factors that can induce stem cell differentiation into endoderm.The first independent claim is:" A method of identifying a factor that promotes the differentiation of human definitive endoderm cells, said method comprising the steps of: obtaining a...
Inventors: D'Amour; Kevin Allen (San Diego, CA), Agulnick; Alan D. (San Marcos, CA), Eliazer; Susan (San Diego, CA), Baetge; Emmanuel E. (Encinitas, CA)
Assignee: Cythera, Inc. (San Diego, CA)
Date of First Priority Issue: Tuesday December 23rd, 2003
Method of generating human retinal progenitors from embryonic stem cells
Patent Number: 7,541,186This patent covers the generation of retinal progenitor cells from embryonic stem cells. Neural stem cells have previously been demonstrated to have ability to differentiate into retinal tissue, as well as embryonic stem cell derived cells. The current patent covers a methodology involving the generation of embryoid...
Inventors: Reh; Thomas (Seattle, WA), Lamba; Deepak (Seattle, WA)
Assignee: University of Washington (Seattle, WA)
Date of First Priority Issue: Wednesday February 22nd, 2006
Method of expanding undifferentiated hemopoietic stem cells
Patent Number: 7,534,609Expansion of hematopoietic stem cells would, at face value, allow the possibility of curing many hematological diseases by the process of selecting non-leukemic stem cells, ex vivo expanding them, and providing them back to the patient after myeloablation has destroyed the resident malignant cells.Pluristem (Nasdaq:PSTI) is developing adult...
Inventors: Merchav; Shoshana (Haifa, IL), Meretski; Shai (Haifa, IL)
Assignee: Pluristem Life Systems Inc. (Haifa, IL)
Date of First Priority Issue: Thursday February 4th, 1999
Pregnancy-induced oligodendrocyte precursor cell proliferation regulated by prolactin
Patent Number: 7,534,765This patent covers the use of prolactin alone or in combinations with other agents for enhancing formation of oligodendrocytes in vivo. It is assigned to the company Stem Cell Therapeutics, out of Calgary Canada, who is currently using hCG and EPO for treatment of strokes in Phase II clinical trials. Other patents owned by Stem Cell Therapeutics include #
Assignee: Stem Cell Therapeutics Inc. (Calgary, Alberta, Canada)
Date of First Priority Issue: Tuesday September 27th, 2005
Growth and differentiation of adult muscle stem cells with activators or inhibitors of Wnt signaling
Patent Number: 7,541,183Depending on extent of injury, bone marrow derived stem cells are known to mobilize and migrate in order to accelerate healing. This has been demonstrated in conditions such as heart attack, stroke, and in critical limb ischemia after administration of exogenous stem cells.Various parts of the body...
Inventors: Rudnicki; Michael (Gloucester, CA), Seale; Patrick (Brookline, MA), Polesskaya; Anna (Villejuif, FR), Fortin; Anouk (Gloucester, CA)
Assignee: Ottawa Health Research Institute (Ottawa, Ontario, CA)
Date of First Priority Issue: Wednesday June 25th, 2003
Angiogenically effective unit dose of FGF-2 and method of use
Patent Number: 7,541,333Stimulation of therapeutic angiogenesis offers great potential, not only for the obvious conditions such as critical limb ischemia and angina, but also for other indications post-stroke recovery and liver failure. Methods of stimulating angiogenesis range from administration of
Assignee: Novartis Vaccines and Diagnostics, Inc. (Emeryville, CA)
Date of First Priority Issue: Tuesday October 13th, 1998
Stem cells and their use in transplantation
Patent Number: 7,537,756The problem with islet transplantation is that one needs 2-3 pancreatic donors per recipient, and even this high number of islets still end up eventually being rejected/nonfunctional. Additionally the recipient needs to be on immune suppression. These drawbacks are not only because of allogeneic issues, but also due to poor vascularization once the islets are injected via the hepatic...
Inventors: Habener; Joel E. (Newton Centre, MA), Zulewski; Hendrik (Basel, CH), Abraham; Elizabeth J. (Quincy, MA), Vallejo; Mario (Madrid, ES), Faustman; Denise L. (Weston, MA), Thomas; Melissa K. (Boston, MA)
Assignee: The General Hospital Corporation (Boston, MA)
Date of First Priority Issue: Monday December 6th, 1999
Methods of producing pancreatic hormones
Patent Number: 7,534,608The company Novocell (merged from Cythera, BresaGen, and Novocell) has been strategically developing an IP portfolio covering numerous aspects of treating diabetes. Having IP on endoderm, as well as encapsulation technologies, the company recently was issued the current patent covering generation of insulin producing cells from embryonic stem cells. The...
Inventors: Martinson; Laura (San Diego, CA), Kroon; Evert (San Diego, CA), D'Amour; Kevin (San Diego, CA), Baetge; Emmanuel Edward (Encinitas, CA)
Assignee: Cythera, Inc. (San Diego, CA)
Date of First Priority Issue: Friday March 2nd, 2007
Compositions and methods for promoting attachment of cells of endothelial cell lineage to medical devices
Patent Number: 7,531,505Lack of proper endothelialization of vascular grafts can cause a variety of problems such as restenosis or thrombosis. The current patent covers a coating for medical devices in which one side of the coating binds to the metallic surface of the device and the other side contains peptides that bind to endothelium or endothelial precursor cells. This patent...
Inventors: Hamilton; Paul Theodore (Cary, NC), Kenan; Daniel James (Chapel Hill, NC), Solan; Amy Katherine (Durham, NC)
Assignee: Affinergy, Inc. (Durham, NC)
Date of First Priority Issue: Wednesday January 11th, 2006
Double nuclear transfer method and results thereof
Patent Number: 7,531,715The area of cloning is of great interest in terms of therapeutics development, not only from the perspective of generating de novo stem cell populations, but also the possibility of making transgenic animals for practical purposes such as food or protein production. Accordingly, numerous patents have been issued on all sorts of variations of the cloning process, as well as...
Inventors: Campbell; Keith H. S. (Leicestershire, GB)
Assignee: PPL Therapeutics (Scotland) (Edinburgh, GB)
Date of First Priority Issue: Wednesday January 13th, 1999